Home » Newsletters » BioWorld Science

BioWorld Science

April 20, 2010

View Archived Issues

NVP-LDE-225: a newly discovered therapeutic candidate for Gorlin's syndrome / News in Context

Nerviano Medical Sciences discloses new pim-1 and pim-2 kinase inhibitors

Phenomix identifies new NS3 NS4A protease inhibitors for HCV infection

Merck Frosst claims new prostanoid DP2 receptor antagonists

Allergan describes novel alpha2B-adrenoceptor antagonists

Merck Frosst discloses new prostanoid EP4 receptor antagonists

Phase III data presented on sodium oxybate in fibromyalgia

Phase II/III data on tafamidis meglumine in TTR-type familial amyloid polyneuropathy

Fab-001 potently active against multiple staphylococcal strains in preclinical study

Ark begins phase I/IIa trial of high-dose VEGF-D in peripheral vascular disease

Phase Ib safety/efficacy data disclosed on SD-101 in treatment-naive hepatitis C

BioMarin launches Firdapse in Europe for Lambert-Eaton myasthenic syndrome

Shionogi and Eli Lilly launch Cymbalta in Japan for depression and depressive symptoms

Javelin terminates merger agreement with Myriad

CSL Behring receives FDA approval to extend shelf life of Privigen

Hygeia Therapeutics to advance development of topical hormone receptor modulators

Meda launches EpiCept's Ceplene in the U.K.

FDA approves BioAlliance's Oravig for oropharyngeal candidiasis

Protein Potential receives NIAID grant to develop malaria vaccine

AMRI and Navigen enter into research collaboration

Takeda obtains five NDA approvals in Japan

Gilead halts phase II trial of GS-9450 in chronic hepatitis C

GSK receives conditional marketing approval for Arzerra in Europe

Dexmedetomidine meets phase III primary endpoint in sedation of ICU patients

Prana Biotechnology set for phase IIb PBT-2 trial in Alzheimer's disease

MTD of EMD-534085 established in phase I trial in advanced solid tumors and lymphoma

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 5, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 5, 2025.
Epigenetic technology could eliminate misfolded prion proteins
BioWorld Science
The number of deaths caused by prion diseases reaches about 30,000 annually. Only 5 months pass from the diagnosis of seemingly healthy patients to the fatal...
Mesothelin is biomarker, potential target in arthritic bone damage
BioWorld Science
In a recent study published in Cell Reports Medicine, researchers from the Institute of Chinese Materia Medica of the China Academy of Chinese Medical Sciences...
Gene therapies aim for the big goal of edits in vivo
BioWorld Science
The field of gene therapy is experiencing major advances driven by precise editing technologies, such as base and prime editing, and by the design of increasingly...